上尿路上皮癌术后辅助化疗

doi:10.3760/cma.j.cn371439-20200227-00052

摘要/Abstract

摘要：

上尿路上皮癌(UTUC)患者手术后复发率高且预后差。既往临床研究结果多数基于回顾性研究,对于术后辅助化疗是否可以改善患者生存尚有争论。近期临床试验结果支持辅助化疗可改善局部晚期UTUC患者的无瘤生存,含铂类药物方案是术后辅助化疗的标准方案。目前尚缺乏术前新辅助化疗与术后辅助化疗对照的临床研究结果,随着靶向治疗及免疫治疗进展,新药联合辅助治疗方案可能会进一步改善UTUC患者生存。

关键词: 泌尿系肿瘤, 化学疗法, 辅助

Abstract:

Upper tract urothelial carcinoma (UTUC) patients have high recurrent rate and poor survival. Most of the previous studies of adjuvant chemotherapy in UTUC were retrospective and the results were controversial. Recent clinical trials support that adjuvant chemotherapy can improve disease-free survival of patients with locally advanced UTUC and platinum based regimens are standard adjuvant treatment. Currently the clinical trials results about effect comparison between adjuvant treatment and neoadjuvant treatment are limited. With the development of targeted therapy and immunotherapy, combinations with novel agents in the adjuvant setting might further improve the prognosis for locally advanced UTUC.

Key words: Urologic neoplasms, Chemotherapy, adjuvant

王墨培, 马力文. 上尿路上皮癌术后辅助化疗[J]. 国际肿瘤学杂志, 2020, 47(7): 436-439.

Wang Mopei, Ma Liwen. Adjuvant chemotherapy for upper tract urothelial carcinoma[J]. Journal of International Oncology, 2020, 47(7): 436-439.

参考文献 24

[1]	Leow JJ, Chong KT, Chang SL, et al. Upper tract urothelial carcinoma: a different disease entity in terms of management[J]. ESMO Open, 2017,1(6):e000126. DOI: 10.1136/esmoopen-2016-000126. doi: 10.1136/esmoopen-2016-000126 pmid: 28848663
[2]	Biswas B, Ganguly S, Ghosh J, et al. Adjuvant chemotherapy for upper tract urothelial carcinoma: is there sufficient evidence?[J]. J Clin Oncol, 2017,35(18):2095-2096. DOI: 10.1200/JCO.2017.72.8600. pmid: 28471709
[3]	杜智勇, 秦川, 申忠华, 等. 高风险上尿路尿路上皮癌辅助化疗疗效分析及预后相关因素研究[J]. 中华泌尿外科杂志, 2016,37(11):808-812. DOI: 10.3760/cma.j.issn.1000-6702.2016.11.004.
[4]	Cohen A, Kuchta K, Park S. Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma[J]. Urol Oncol, 2017,35(6):322-327. DOI: 10.1016/j.urolonc.2016.11.018. pmid: 28065502
[5]	Quhal F, Mori K, Sari Motlagh R, et al. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis[J]. Int J Clin Oncol, 2020,25(6):1037-1054. DOI: 10.1007/s10147-020-01650-9. doi: 10.1007/s10147-020-01650-9 pmid: 32206939
[6]	Ikeda M, Matsumoto K, Hirayama T, et al. Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study[J]. Clin Genitourin Cancer, 2018,16(3):e669-e675. DOI: 10.1016/j.clgc.2017.10.014. doi: 10.1016/j.clgc.2017.10.014 pmid: 29239844
[7]	Lee KS, Kim KH, Yoon YE, et al. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy[J]. Korean J Urol, 2015,56(1):41-47. DOI: 10.4111/kju.2015.56.1.41. doi: 10.4111/kju.2015.56.1.41 pmid: 25598935
[8]	罗勇, 冯炳富, 魏德超, 等. 辅助化疗对高危上尿路尿路上皮癌患者生存预后影响的前瞻性对照观察[J]. 中华医学杂志, 2019,99(40):3158-3163. DOI: 10.3760/cma.j.issn.0376-2491.40.007.
[9]	Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer[J]. Cancer, 2015,121(15):2586-2593. DOI: 10.1002/cncr.29387. doi: 10.1002/cncr.29387 pmid: 25872978
[10]	Shirotake S, Kikuchi E, Tanaka N, et al. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience[J]. J Urol, 2015,193(4):1122-1128. DOI: 10.1016/j.juro.2014.10.022. doi: 10.1016/j.juro.2014.10.022 pmid: 25444957
[11]	Leow JJ, Martin-Doyle W, Fay AP, et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma[J]. Eur Urol, 2014,66(3):529-541. DOI: 10.1016/j.eururo.2014.03.003. doi: 10.1016/j.eururo.2014.03.003 pmid: 24680361
[12]	Yafi FA, Tanguay S, Rendon R, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome[J]. Urol Oncol, 2014, 32(1): 31.e17-31.e3.1E24. DOI: 10.1016/j.urolonc.2012.11.014. doi: 10.1016/j.urolonc.2012.11.014
[13]	Singla N, Hutchinson R, Menegaz C, et al. Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma[J]. Urology, 2016,96:44-53. DOI: 10.1016/j.urology.2016.07.015. doi: 10.1016/j.urology.2016.07.015 pmid: 27443467
[14]	Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2020,395(10232):1268-1277. DOI: 10.1016/S0140-6736(20)30415-3. doi: 10.1016/S0140-6736(20)30415-3 pmid: 32145825
[15]	Gregg RW, Vera-Badillo FE, Booth CM, et al. Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2018,128:58-64. DOI: 10.1016/j.critrevonc.2018.05.005. pmid: 29958631
[16]	Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma[J]. J Clin Oncol, 2017,35(8):852-860. DOI: 10.1200/JCO.2016.69.4141. pmid: 28045620
[17]	Kim DK, Lee JY, Kim JW, et al. Effect of neoadjuvant chemo-therapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2019,135:59-65. DOI: 10.1016/j.critrevonc.2019.01.019. doi: 10.1016/j.critrevonc.2019.01.019 pmid: 30819447
[18]	Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy[J]. Oncologist, 2019,24(4):563-569. DOI: 10.1634/theoncologist.2018-0084. pmid: 30541754
[19]	Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2017,18(2):212-220. DOI: 10.1016/S1470-2045(17)30007-4. pmid: 28081914
[20]	Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase Ⅱ IMvigor210 study[J]. Ann Oncol, 2017,28(12):3044-3050. DOI: 10.1093/annonc/mdx518. pmid: 28950298
[21]	Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2017,389(10064):67-76. DOI: 10.1016/S0140-6736(16)32455-2. doi: 10.1016/S0140-6736(16)32455-2 pmid: 27939400
[22]	Inokuchi J, Yokomizo A, Nishiyama N, et al. Perioperative therapies for urological cancers[J]. Jpn J Clin Oncol, 2020,50(4):357-367. DOI: 10.1093/jjco/hyaa013. doi: 10.1093/jjco/hyaa013 pmid: 32115649
[23]	Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma[J]. Eur Urol, 2017,72(4):641-649. DOI: 10.1016/j.eururo.2017.05.048. doi: 10.1016/j.eururo.2017.05.048 pmid: 28601352
[24]	Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma[J]. N Engl J Med, 2019,381(4):338-348. DOI: 10.1056/NEJMoa1817323. doi: 10.1056/NEJMoa1817323 pmid: 31340094